Mantoux test: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{SI}}
{{SI}}
{{CMG}}
{{CMG}}; {{AE}} {{AL}}


{{SK}} PPD, TB skin test
{{SK}} PPD, TB skin test

Revision as of 14:25, 4 September 2014

WikiDoc Resources for Mantoux test

Articles

Most recent articles on Mantoux test

Most cited articles on Mantoux test

Review articles on Mantoux test

Articles on Mantoux test in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mantoux test

Images of Mantoux test

Photos of Mantoux test

Podcasts & MP3s on Mantoux test

Videos on Mantoux test

Evidence Based Medicine

Cochrane Collaboration on Mantoux test

Bandolier on Mantoux test

TRIP on Mantoux test

Clinical Trials

Ongoing Trials on Mantoux test at Clinical Trials.gov

Trial results on Mantoux test

Clinical Trials on Mantoux test at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mantoux test

NICE Guidance on Mantoux test

NHS PRODIGY Guidance

FDA on Mantoux test

CDC on Mantoux test

Books

Books on Mantoux test

News

Mantoux test in the news

Be alerted to news on Mantoux test

News trends on Mantoux test

Commentary

Blogs on Mantoux test

Definitions

Definitions of Mantoux test

Patient Resources / Community

Patient resources on Mantoux test

Discussion groups on Mantoux test

Patient Handouts on Mantoux test

Directions to Hospitals Treating Mantoux test

Risk calculators and risk factors for Mantoux test

Healthcare Provider Resources

Symptoms of Mantoux test

Causes & Risk Factors for Mantoux test

Diagnostic studies for Mantoux test

Treatment of Mantoux test

Continuing Medical Education (CME)

CME Programs on Mantoux test

International

Mantoux test en Espanol

Mantoux test en Francais

Business

Mantoux test in the Marketplace

Patents on Mantoux test

Experimental / Informatics

List of terms related to Mantoux test

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Synonyms and keywords: PPD, TB skin test

Overview

The Mantoux tuberculin skin test (TST) is the standard method of determining whether a person is infected with Mycobacterium tuberculosis. Reliable administration and reading of the TST requires standardization of procedures, training, supervision, and practice.

Procedure

The TST is performed by injecting 0.1 ml of tuberculin purified protein derivative (PPD) into the inner surface of the forearm. The injection should be made with a tuberculin syringe, with the needle bevel facing upward. The TST is an intradermal injection. When placed correctly, the injection should produce a pale elevation of the skin (a wheal) 6 to 10 mm in diameter.

The skin test reaction should be read between 48 and 72 hours after administration. A patient who does not return within 72 hours will need to be rescheduled for another skin test.

The reaction should be measured in millimeters of the induration (palpable, raised, hardened area or swelling). The reader should not measure erythema (redness). The diameter of the indurated area should be measured across the forearm (perpendicular to the long axis).

Classification of Tuberculin Reaction

Skin test interpretation depends on two factors:

  • Measurement in millimeters of the induration.
  • Person’s risk of being infected with TB and of progression to disease if infected.
Image from Public Health Image Library (PHIL)
Image from Public Health Image Library (PHIL)
Tuberculin Reaction Considered a Positive Result in:
≥ 5 mm
  • HIV-positive person
  • Recent contacts of TB case
  • Persons with nodular or fibrotic changes on CXR consistent with old healed TB
  • Patients with organ transplants and other immunosuppressed patients
≥ 10 mm
  • Recent arrivals (less than 5 years) from high-prevalent countries
  • Injection drug users
  • Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes, hospitals, homeless shelters)
  • Mycobacteriology lab personnel
  • Persons with clinical conditions that place them at high risk (e.g., diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes, low body weight)
  • Children less than 4 years of age, or children and adolescents exposed to adults in high-risk categories
≥ 15 mm
  • Persons with no known risk factors for TB
Table adapted from CDC[1]

Contraindications

TST is contraindicated only for persons who have had a severe reaction (e.g., necrosis, blistering, anaphylactic shock, or ulcerations) to a previous TST. It is not contraindicated for any other persons, including infants, children, pregnant women, persons who are HIV-infected, or persons who have been vaccinated with BCG.

False-Poisitve and False-Negative Reactions

In some persons who are infected with M. tuberculosis, the ability to react to tuberculin may wane over time. When given a TST years after infection, these persons may have a false-negative reaction. However, the TST may stimulate the immune system, causing a positive, or boosted reaction to subsequent tests. Giving a second TST after an initial negative TST reaction is called two-step testing.

False-Positive Reactions False-Negative Reactions
Some persons may react to the TST even though they are not infected with M. tuberculosis. The causes of these false-positive reactions may include, but are not limited to, the following:
  • Infection with nontuberculosis mycobacteria
  • Previous BCG vaccination
  • Incorrect method of TST administration
  • Incorrect interpretation of reaction
  • Incorrect bottle of antigen used

Some persons may not react to the TST even though they are infected with M. tuberculosis. The reasons for these false-negative reactions may include, but are not limited to, the following:

  • Cutaneous anergy (anergy is the inability to react to skin tests because of a weakened immune system)
  • Recent TB infection (within 8-10 weeks of exposure)
  • Very old TB infection (many years)
  • Very young age (less than 6 months old)
  • Recent live-virus vaccination (e.g., measles and smallpox)
  • Overwhelming TB disease
  • Some viral illnesses (e.g., measles and chicken pox)
  • Incorrect method of TST administration
  • Incorrect interpretation of reaction
Table adapted from CDC[1]

Two-step Testing

Two-step testing is useful for the initial skin testing of adults who are going to be retested periodically, such as health care workers or nursing home residents. This two-step approach can reduce the likelihood that a boosted reaction to a subsequent TST will be misinterpreted as a recent infection.

See also

References

  1. 1.0 1.1 "CDC Tuberculin Skin Testing".

be-x-old:Рэакцыя Манту it:Mantoux test nl:Mantouxtest no:Mantoux-metoden


Template:WikiDoc Sources